| Name | Title | Contact Details |
|---|
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
National Medical Development Inc is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
First Assist is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Duchesnay is a Laval, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Drake-Scruggs Equipment Inc is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.